Radiopharmaceutical CDMO/CMO Services Market Enable Precision Medicine through Technological Innovation and Strategic Partnerships

Radiopharmaceutical CDMO/CMO Services Market Size is valued at USD 2.9 Billion in 2024 and is predicted to reach USD 7.0 Billion by the year 2034 at a 9.2% CAGR during the forecast period for 2025-2034.

Latest Drivers Restraint and Opportunities Market Snapshot:

Key factors influencing the global radiopharmaceutical CDMO/CMO services market are:

• Growing prevalence of cancer
• Growing interest in personalized treatment
• Technological advancements

The following are the primary obstacles to the radiopharmaceutical CDMO/CMO services market’s expansion:

• High cost
• Inadequate infrastructure
• Shortages of skilled workers

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2472

Future expansion opportunities for the global radiopharmaceutical CDMO/CMO services market include:

• Growing use of nuclear therapy in underdeveloped nations
• Increasing investments in research and development
• Increased partnership with pharmaceutical industries

Key Industry Insights & Findings from the report:

• The market is growing rapidly due to supportive government initiatives and technological advancements.
• The market for radiopharmaceutical CDMO/CMO services is driven by the increasing incidence of cancer and pharmaceutical firms outsourcing manufacturing to save costs and comply with regulations.
• North America dominated the market and accounted for a revenue share of global revenue in 2023.
• High costs and lack of infrastructure are major issues impeding industry expansion.

Market Analysis:

The radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) and Contract Manufacturing Organization (CMO) services market is witnessing substantial growth, fueled by the rising prevalence of cardiovascular diseases and cancer, as well as the expanding demand for nuclear-based therapies and innovations in radiopharmaceutical technologies.

Strong governmental backing, increased investments in research and development, and the progressive adoption of advanced medical imaging applications are key factors driving market expansion. Furthermore, the heightened focus on personalized medicine and the growing need for customized therapeutic solutions are reinforcing the adoption of radiopharmaceutical contract development and manufacturing services.

List of Prominent Players in the Radiopharmaceutical CDMO/CMO Services Market:

• Minerva Imaging
• Evergreen Theragnostics, Inc.
• NMR (NorthStar Medical Radioisotopes
• PharmaLogic
• Eckert & Ziegler
• AtomVie
• Eczac?ba??-Monrol
• Cardinal Health
• Nucleus RadioPharma
• Seibersdorf Labor GmbH
• Global Medical Solutions
• SOFIE
• SpectronRx
• Agilera Pharma AS
• Siemens Healthineers
• Grupo RPH
• Almac Group
• Medi-Radiopharma
• Itm Radiopharma
• Nihon Medi-Physics Co., Ltd.
• IONETIX Corporation
• GBI
• DuchemBio, Co., Ltd

Expert Knowledge, just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-03

Recent Developments:

• In February 2024, the clinical-stage radiopharmaceutical company Evergreen Theragnostics, Inc. announced that it has partnered and licensed with the Medical University of Innsbruck, a preeminent European research institution, to promote the development of innovative radiopharmaceuticals.
• In February 2025, Lantheus Holdings, Inc. announced a definitive agreement to acquire Evergreen Theragnostics, Inc. (“Evergreen”) in an all-cash transaction that includes a $250 million upfront payment and up to an additional $752.5 million in potential milestone payments. The company is dedicated to helping clinicians Find, Fight, and Follow disease to improve patient outcomes.
• In October 2024, Atley Solutions delivered and installed the first commercial unit at Minerva Imaging’s facilities in Denmark, following the regulatory approval and launch of the world’s first commercial module for making Astatine-211 (At-211) radiopharmaceuticals. With the release of the Atley C100, Atley Solutions has achieved a major technical and business milestone, solidifying its position as a world leader in commercial products and services for At-211 radiopharmaceuticals.

Radiopharmaceutical CDMO/CMO Services Market Dynamics

Market Drivers: Technological Advancements

The growth of the radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) and Contract Manufacturing Organization (CMO) services market is primarily driven by continuous technological innovation.

Developments in artificial intelligence (AI)-enabled imaging, automated radiopharmaceutical production, and advancements in nuclear medicine are enhancing the precision, efficiency, and effectiveness of therapeutic interventions.

Innovations in drug formulation, the introduction of novel isotopes, and the creation of personalized radiotherapies are further contributing to improved patient outcomes. Additionally, progress in quality assurance, regulatory compliance, and radiopharmaceutical synthesis is optimizing production workflows, thereby supporting sustained market expansion.

Challenges: High Operational Costs

Market growth is constrained by the high operational costs associated with radiopharmaceutical CDMO/CMO services. Significant expenses arise from raw materials, specialized production processes, and strict regulatory requirements.

The short half-life of radioisotopes necessitates specialized logistics, while the need for purpose-built facilities, trained personnel, radiation safety protocols, and rigorous quality control systems further increases operational expenditures. These factors collectively limit scalability and market accessibility, posing obstacles to broader adoption.

Regional Outlook: North America

North America is projected to dominate the radiopharmaceutical CDMO/CMO services market, exhibiting the highest compound annual growth rate (CAGR) over the forecast period. This expansion is supported by growing demand for nuclear medicine, a rising prevalence of cancer and cardiovascular conditions, and significant research and development investments in the radiopharmaceutical sector.

The region benefits from a robust healthcare infrastructure, well-defined regulatory frameworks, and strong governmental support. Additionally, the presence of leading pharmaceutical companies, specialized CDMOs, and ongoing advancements in targeted radiotherapies are expected to sustain and accelerate market growth in North America.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2472

Segmentation of Radiopharmaceutical CDMO/CMO Services Market-

By Application-

• Diagnostic Radiopharmaceuticals
• Therapeutic Radiopharmaceuticals

By Type of Radioisotope-

• Technetium-99m
• Fluorine-18
• Leutetium-177
• Gallium-68
• Actinium-225
• Others

By Source of Manufacturing-

• Nuclear Reactors
• Cyclotrons

By Scale of Operation-

• Preclinical
• Clinical
• Commercial

By Therapeutic Area-

• Cardiovascular Disorders
• Neurological Disorders
• Oncological Disorders
• Others

By Region-

North America-

• The US
• Canada
• Mexico

Europe-

• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific-

• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific

Latin America-

• Brazil
• Argentina
• Rest of Latin America

 Middle East & Africa-

• GCC Countries
• South Africa
• Rest of Middle East and Africa

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Tags: Radiopharmaceutical CDMO/CMO Services Market